

# Jessica K Dyson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/829552/publications.pdf>

Version: 2024-02-01

37  
papers

2,138  
citations

393982

19  
h-index

315357

38  
g-index

38  
all docs

38  
docs citations

38  
times ranked

3501  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team. <i>Journal of Hepatology</i> , 2014, 60, 110-117.	1.8	487
2	Primary sclerosing cholangitis. <i>Lancet, The</i> , 2018, 391, 2547-2559.	6.3	276
3	Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. <i>Frontline Gastroenterology</i> , 2014, 5, 211-218.	0.9	254
4	Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK. <i>Lancet, The</i> , 2018, 391, 1097-1107.	6.3	140
5	Novel therapeutic targets in primary biliary cirrhosis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 147-158.	8.2	110
6	Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. <i>Journal of Hepatology</i> , 2016, 64, 234-238.	1.8	85
7	Implementation of the Lancet Standing Commission on Liver Disease in the UK. <i>Lancet, The</i> , 2015, 386, 2098-2111.	6.3	76
8	The New Epidemiology of Primary Biliary Cirrhosis. <i>Seminars in Liver Disease</i> , 2014, 34, 318-328.	1.8	66
9	Unmet clinical need in autoimmune liver diseases. <i>Journal of Hepatology</i> , 2015, 62, 208-218.	1.8	56
10	The Impact of Autoimmune Hepatitis and Its Treatment on Health Utility. <i>Hepatology</i> , 2018, 68, 1487-1497.	3.6	48
11	Treatment of Non-Alcoholic Fatty Liver Disease. <i>Digestive Diseases</i> , 2014, 32, 597-604.	0.8	39
12	Response to the NCEPOD report: development of a care bundle for patients admitted with decompensated cirrhosis—the first 24 h. <i>Frontline Gastroenterology</i> , 2016, 7, 16-23.	0.9	36
13	Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 951-960.	1.9	34
14	New metrics for the Lancet Standing Commission on Liver Disease in the UK. <i>Lancet, The</i> , 2017, 389, 2053-2080.	6.3	33
15	Review article: unanswered clinical and research questions in autoimmune hepatitis—conclusions of the International Autoimmune Hepatitis Group Research Workshop. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 528-536.	1.9	33
16	Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. <i>Journal of Hepatology</i> , 2022, 77, 1545-1553.	1.8	33
17	Changes in natural killer cells and exhausted memory regulatory T Cells with corticosteroid therapy in acute autoimmune hepatitis. <i>Hepatology Communications</i> , 2018, 2, 421-436.	2.0	31
18	Fatigue in primary sclerosing cholangitis is associated with sympathetic overactivity and increased cardiac output. <i>Liver International</i> , 2015, 35, 1633-1641.	1.9	27

#	ARTICLE	IF	CITATIONS
19	Geo-epidemiology and environmental co-variate mapping of primary biliary cholangitis and primary sclerosing cholangitis. <i>JHEP Reports</i> , 2021, 3, 100202.	2.6	22
20	Pregnancy outcomes in women with liver transplants: systematic review and meta-analysis. <i>Hpb</i> , 2020, 22, 1102-1111.	0.1	19
21	Early Molecular Stratification of High-risk Primary Biliary Cholangitis. <i>EBioMedicine</i> , 2016, 14, 65-73.	2.7	17
22	Understanding and Treating Fatigue in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. <i>Clinics in Liver Disease</i> , 2016, 20, 131-142.	1.0	16
23	Adult parenteral nutrition in the North of England: a region-wide audit. <i>BMJ Open</i> , 2017, 7, e012663.	0.8	16
24	Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. <i>Hepatology</i> , 2022, 75, 13-27.	3.6	16
25	Hepatitis B in pregnancy. <i>Frontline Gastroenterology</i> , 2014, 5, 111-117.	0.9	14
26	Managing cognitive symptoms and fatigue in cholestatic liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 235-241.	1.4	13
27	Review article: experimental therapies in autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1134-1149.	1.9	12
28	Fatal gastrointestinal histoplasmosis 15 years after orthotopic liver transplantation. <i>World Journal of Gastroenterology</i> , 2017, 23, 7807-7812.	1.4	12
29	Paediatric to adult liver transition services: the state of play in the UK. <i>Clinical Medicine</i> , 2019, 19, 425-426.	0.8	12
30	Prior hysterectomy and discomfort during colonoscopy: a retrospective cohort analysis. <i>Endoscopy</i> , 2014, 46, 493-498.	1.0	11
31	Pembrolizumab as a Cause of Cholangiopathy in a Patient With Metastatic Melanoma. <i>Hepatology</i> , 2020, 71, 2164-2166.	3.6	11
32	Diagnosis and management of patients with primary biliary cirrhosis. <i>Clinical Liver Disease</i> , 2014, 3, 52-55.	1.0	8
33	Lesson of the month 2: Severe reactivation of hepatitis B after immunosuppressive chemotherapy. <i>Clinical Medicine</i> , 2014, 14, 551-555.	0.8	6
34	Reply to "Liver failure in human immunodeficiency virus" Hepatitis C virus coinfection treated with sofosbuvir, ledipasvir and antiretroviral therapy. <i>Journal of Hepatology</i> , 2016, 64, 753-754.	1.8	4
35	Bezafibrate for the Treatment of Cholestatic Pruritus: Time for a Change in Management?. <i>Gastroenterology</i> , 2021, 160, 649-651.	0.6	3
36	Patient Priorities in Autoimmune Hepatitis: The Need for Better Treatments, More Education and Challenging Stigma. <i>Digestive Diseases and Sciences</i> , 2022, , .	1.1	3

#	ARTICLE	IF	CITATIONS
37	UDCA prophylaxis for post-transplant PBC recurrence prevention: Time to change practice. Journal of Hepatology, 2020, 73, 499-501.	1.8	2